Compare AbCellera Biologics Inc (ABCL) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Cenovus Energy Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Cenovus Energy Inc trades at $26.41 (market cap $47.02B). The key difference: Cenovus Energy Inc is far larger — about 20× AbCellera Biologics Inc's market cap, and Cenovus Energy Inc pays a 2.46% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CVE | |
|---|---|---|
Market Cap | $2.35B | $47.02B |
Sector | Health | Energy |
52-Week High | $8.12 | $31.80 |
52-Week Low | $2.78 | $13.96 |
Enterprise Value | $1.99B | $54.90B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Cenovus Energy (CVE) trades at $25.21, up 2.27% with a bearish technical signal. Recent earnings beats and an attractive P/E of 13.78 highlight fundamental strength, while cash flow trends show operational resilience despite negative net flows. The company maintains a solid balance sheet with a debt-to-asset ratio of 13.63% as of 2024.
CVE offers value with low valuation multiples and consistent profitability, but faces headwinds from volatile oil prices and regulatory challenges. Analyst consensus is mixed with 40.74% buy ratings, suggesting cautious optimism for long-term growth amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
